June 2012 Issue of MMM
June 2012 issue
Not all gizmos are at war with mobile. In healthcare, it's become the opposite.
Medical devices that are part app, part consumer gadget are spurring changes. Plus: Video of patient comments in our "Patient POV" sidebar
DNA sequencing is becoming economical for clinical trials and cancer management. It's also expected to move into primary care physicians' offices. We look at the ...
What do device agencies and clients want from each other? Two experts give their views on the secrets to great working relationships
Former ABC exec Paul Slavin is building a broadcast powerhouse at Everyday Health
Unmet need is driving more R&D and treatment options for rheumatoid arthritis—but it won't be easy for any newcomer to challenge the nine RA biologics ...
In a fast-changing industry, a constant is how the limited number of patients for trials hinders drug development
I find Qnexa andLorcaserin problematic, and would be reluctant to prescribe them, at least initially
Scientists are getting closer to finding the killer app in treating hepatitis C, but it may be too soon to pick a winner.
When Pfizer's US Enbrel sales force gives way to Amgen's in July, reps risk layoff if they don't get picked up by Amgen or re-assigned ...
Novo Nordisk advised employees it was looking to hire for 615 US positions—a 15% expansion of its US workforce.
News on Eisai, Eli Lilly and Veeva
Med Ed Report
A free CD-ROM launched by Purdue in May aims to help providers better assess pain patients and document visits
The steady stream of big pharma firms settling with the feds and states for alleged off-label marketing continued with Abbott Labs in May.
The number of ACCME-accredited and state or territorial medical society accredited CME providers fell a respective 9% and 18% the last five years.
News on Sermo, Morehead, Happtique, ACCME and DMD
An email from Harvard University's Faculty Advisory Council over the cost of professional journals has touched off the latest round in the universities vs publishers ...
JAMA is focusing more attention on its Viewpoint feature, in which the editor chooses a topic, picks a panel of experts and pits them against ...
News on DMD , Elsevier and Springer
Harvard has urged faculty to abandon costly journals for open-access ones or those with "reasonable, sustainable subscription costs." Will this be a tipping point in ...
Doximity announced that it is creating an app just for Stanford Medical School students and alumni.
A sizable study of four primary care clinics serving low income communities in New York found that text messaging is an effective way to remind ...
News on Manhattan Research, Enspektos, Everyday Health and Happtique
Co-pay coupons may lead more than 2 million seniors to opt for more expensive branded drugs, despite a prohibition on the use of coupons through ...
Animation lends a light touch to an otherwise heavy category in a campaign for Abilify.
Amgen attributed the thousand or so new Prolia patients the company saw in the first quarter of 2012 to its ad campaign with Blythe Danner.
Symphony Technology Group, a private equity firm, acquired the healthcare analytics business of Wolters Kluwer, the companies said.
Private-equity firm Veritas Capital will buy the healthcare business of Thomson Reuters for $1.25 billion in cash.
Saatchi & Saatchi Innovations, Publicis' Pennsylvania-based outpost servicing specialty pharma, is rebranding as Saatchi Science.
The National Bone Health Alliance and inVentiv shop GSW Worldwide are launching 2Million2Many, an education campaign to raise awareness of the connection between osteoporosis and ...
IMC2 Health and Wellness' mainline sibling IMC2 is rebranding as MEplusYOU
News on McCann Healthcare Worldwide Japan, the Hal Lewis Group, Walgreens and Publicis Groupe
Social media is messy and the regulatory framework is equally so. Get used to it.
Legislation to speed FDA approval of breakthrough drugs is being supported by both former FDA commissioner Mark McClellan, now a Brookings Institution senior fellow, and ...
An FDA report says the agency issued 68 drug safety alerts in 2011, an average of more than one each week and up 74% over ...
A new way of looking at regulation of devices and other innovations may be the real cure for what ails us
Many PR pros hinder their clients' and employers' ability to reach target audiences through the media
Abby Mansfield, SVP, Creative Director at Topin & Associates.
At Work With
Susan Hanks, Senior Vice President, M/A/R/C Research
Daniel L. Menichella, Chief Business Officer, Zyngenia
Manufacturer, market research and agency hires and promotions
Name That Brand
Brand X tries to reinforce its strength
Military communication has an urgency that you can't match in the business world
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.